| abstract |
As an example of investigating the accumulation of chondroitin sulfate proteoglycan (CSPG), the invention relates to a nerve fiber degeneration inhibitor which is for a treatment by an siRNA of N-acetylgalactosamine-4-O-sulfotransferase: N-acetylgalactosamine-4-O-sulfotransferase-1, N-acetylgalactosamine-4-O-sulfotransferase-2, N-acetylgalactosamine-4-sulfate 6-O-sulfotransferase (GalNAc4ST-1, GalNAc4ST-2, GalNAc4S-6ST) being a sulfotransferase of acetylgalactosamine being a side chain of chondroitin sulfate proteoglycan and chondroitinase ABC being an enzyme degrading chondroitin sulfate being a side chain and suitable for gene therapy or prevention for a nerve fiber degeneration disease inducing cell death of neurons accompanying the accumulation of abnormal protein. |